Register Early To Save
Enrol before 13 September to save 20% (October Course)
Discount has been applied to the price above. VAT, if applicable, will be added.
£396.00 – £495.00
1-day live online training |Â Develop effective regulatory strategies when working with the FDA – Click Here to Download the Agenda
Discount has been applied to the price above. VAT, if applicable, will be added.
Learn more about the course by toggling through the tabs below. Scroll down to view the agenda, trainer info and who should attend.
To place your pharmaceutical, biotech of advanced therapy on the US market you must first gain FDA regulatory approval. Like all regulatory agencies, the FDA process requires skill and knowledge to navigate efficiently and to ensure fast approval.
This FDA regulatory training course examines the processes, terminology and best practices to ensure your interactions with the FDA are positive. Once completed, you will have the confidence to successfully submit Investigational New Drug Applications (IND) and New Drug Applications (NDA). You will learn the practical regulatory skills to get your pharmaceutical or biotech approved by FDA reviewers. You will also learn how best to gain approval for generics and biosimilars.
You can view the agenda by scrolling down on this page. If you would like to receive a PDF version with all the course information, please complete the form below.
Find out when this course is running so you can plan your training. Scroll down to view the full agenda.
1-Day Live Online Training
Register at the top of the page.
1-Day Live Online Training
Register at the top of the page.
1-Day Live Online Training
Register at the top of the page.
If you want to train a small group, we offer a group discount between 5% and 50% depending on the course and number of attendees.
For a quote, complete our contact form by following the link. Get in touch.
We also design and deliver fully customised team training focused on your products, processes, technologies and challenges. This is ideal for specific training requirements or larger groups. Please get in touch with us for more information.
For more information, complete our contact form by following the link. Get in touch.
Learn more about the course by toggling through the tabs below (Agenda, Trainer and Who Should Attend?)
Course Information
10 October 2024
10 April 2025
26 November 2025
180 mins | 9:30 AM UK
Overview of the US Food and Drug Administration (FDA)
Â
Examining the drug development regulations in the US
FDA Meetings
10 October 2024
10 April 2025
26 November 2025
180 mins | 1:30 PM UK
Evaluation of FDA review options
Understanding the following FDA review options:
Reviewing the NDA process /BLA Process
ANDA (Generics) and 351K (Biosimilars)
Additional Considerations
Andrew Willis is a regulatory and Development consultant with 30 years of experience. Andrew’s management roles have seen him act as global Vice President of Regulatory Affairs and Medical Affairs, creating business for complex pharmaceutical development projects. Andrew has gained therapeutic experience in areas covering CNS, oncology, urology and pain management.
Experienced with both EU and US applications (NDA, 505 B 2, ANDA, BLA, MAA) for NCEs, generics and line extensions, with particular knowledge of sterile and biotech products. Andrew’s experience covers multiple applications, scientific advice meetings and orphan drug applications. He has significant experience with novel drug delivery systems has been utilized in all the above type of applications.
Andrew continues to provide training for all major companies and also a number of EU Member states agencies in CMC, variations and advanced regulatory affairs. He currently delivers extensive training courses on the EU and US, specifically looking at QbD, CMC regs and lifecycle management. Andrew has delivered multiple courses on FDA regulatory affairs, supporting professionals with their FDA submissions. He has delivered FDA regulatory courses on a range of products such as pharmaceuticals, biotech, cell and gene, generics and biosimilars.
This course is aimed at professionals who work in regulatory affairs and are involved in the approval of therapeutics in the US. These include:
University of Nebraska Medical Center –
n/a
IASIS PHARMACEUTICALS HELLAS –
n/a
Individual Booking (verified owner) –
n/a
RaoufAzizi –
I want to travel can you give me a visa
Fresenius Kabi. –
A very informative, experienced presenter
Ipsen –
Detailed and pragmatic journey through FDA-driven processes, stakeholders and meetings.
Blue Pharma –
Great course to understand US FDA specific interactions with the Applicant/MAH from development to life cycle management.
Pfizer –
An interesting overview of FDA regulatory process, it was a small group which allowed for asking many questions
Individual Booking (verified owner) –
Very well organized. I found it very engaging and the speaker was very confident and knowledgeable.